AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

6.7M

Current Price

$0.10
+0.0050 (+5.5494%)

Book Price

$-0.24
Overvalued by 347.84%
Financial Institution

Company Metrics

  • 2.25 P/E
  • 131.22 P/S
  • 1.07 P/B
  • 0.0820 EPS
  • 0.05 / N/A % Dividend
  • 62,066.00 Avg. Vol.
  • 37.45M Shares
  • 6.7M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax, Inc. (AFFY): Affymax Likely Worthless: Omontys Kills At Least 9x More ...
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax, Inc. (AFFY): Affymax: Putting The Pieces Together [Amgen, Inc ...
Seeking Alpha - Aug 24, 2013
Affymax's sole drug product is OMONTYS┬« (peginesatide) Injection ("OMONTYS"), which was approved by the FDA in 2012 and well received by the medical community as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on ...
Affymax, Inc. (AFFY): Affymax: Emerging Data Supports Conclusion Omontys ...
Seeking Alpha - Nov 12, 2013
The FDA data, combined with the lack of commentary about Omontys on Fresenius' (NYSE:FMS) or Takeda's (OTCPK:TKPHF) latest earnings calls and the cash burn at Affymax (OTCPK:AFFY), all lead us to believe that the end is near for Affymax.
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (AFFY): Don't Believe In Affymax - The Stock Is Probably Worthless
Seeking Alpha - Aug 29, 2013
Investors in Affymax (OTCPK:AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the ...
Affymax, Inc. (OTCMKTS:AFFY) With a Promising Start of The Week
HotStocked - Jul 30, 2013
Affymax, Inc. (OTCMKTS:AFFY, AFFY message board) had a long period in which they were virtually going nowhere as they were hovering around the $1 mark.
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Telestone Technologies Corp.
Affymax, Inc. (AFFY): Just Like Omontys.com, Affymax Is Likely To Disappear
Seeking Alpha - Sep 10, 2013
Past case studies can provide important information about how current events are likely to play out. Regarding Affymax (OTCPK:AFFY), we conducted in depth research looking for past examples of drugs that had been subject to recalls and subsequently ...
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
The end for Affymax (AFFY)
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News